↓ Skip to main content

SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma

Overview of attention for article published in Clinical and Molecular Allergy, April 2017
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
36 Dimensions

Readers on

mendeley
34 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma
Published in
Clinical and Molecular Allergy, April 2017
DOI 10.1186/s12948-017-0065-4
Pubmed ID
Authors

G. Senna, M. Guerriero, P. L. Paggiaro, F. Blasi, M. Caminati, E. Heffler, M. Latorre, G. W. Canonica, on Behalf of SANI

Abstract

Even if severe asthma (SA) accounts for 5-10% of all cases of the disease, it is currently a crucial unmet need, owing its difficult clinical management and its high social costs. For this reason several networks, focused on SA have been organized in some countries, in order to select these patients, to recognize their clinical features, to evaluate their adherence, to classify their biological/clinical phenotypes, to identify their eligibility to the new biologic therapies and to quantify the costs of the disease. Aim of the present paper is to describe the ongoing Italian Severe Asthma Network (SANI). Up today 49 centres have been selected, widespread on the national territory. Sharing the same diagnostic protocol, data regarding patients with SA will be collected and processed in a web platform. After their recruitment, SA patients will be followed in the long term in order to investigate the natural history of the disease. Besides clinical data, the cost/benefit evaluation of the new biologics will be verified as well as the search of peculiar biomarker(s) of the disease.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 34 100%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 4 12%
Professor 3 9%
Other 3 9%
Student > Bachelor 3 9%
Researcher 3 9%
Other 8 24%
Unknown 10 29%
Readers by discipline Count As %
Medicine and Dentistry 17 50%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Economics, Econometrics and Finance 1 3%
Nursing and Health Professions 1 3%
Psychology 1 3%
Other 1 3%
Unknown 12 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 April 2017.
All research outputs
#20,413,129
of 22,963,381 outputs
Outputs from Clinical and Molecular Allergy
#196
of 214 outputs
Outputs of similar age
#270,227
of 310,129 outputs
Outputs of similar age from Clinical and Molecular Allergy
#8
of 8 outputs
Altmetric has tracked 22,963,381 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 214 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,129 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one.